StoxBiocon vs Abbott India: share price & financials comparison
NSE: BIOCON vs ABBOTINDIA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Biocon vs Abbott India at a glance
Biocon (BIOCON) has a market capitalisation of ₹59,497 Cr, against ₹55,983 Cr for Abbott India (ABBOTINDIA). Over the past year Biocon has returned -2.3%, compared with -11.3% for Abbott India. On valuation, Abbott India trades at a lower P/E of 34.7 versus 131.6. Abbott India comes out ahead on valuation, profitability, growth and technicals. Across the scored metrics below, Biocon leads on 3 and Abbott India on 9. On StoxGud's 10-point checklist, Biocon scores 3/10 and Abbott India scores 5/10.
| Metric | Biocon | Abbott India |
|---|---|---|
| Size | ||
| Market cap | ₹59,497 Cr | ₹55,983 Cr |
| Revenue (latest FY) | ₹16,927 Cr | — |
| Net profit (latest FY) | ₹386 Cr | — |
| Valuation | ||
| P/E | 131.6 | 34.7 |
| P/B | 1.71 | — |
| Dividend yield | 0.15% | — |
| Profitability | ||
| Return on equity | 1.3% | — |
| Net profit margin | 2.6% | 23.1% |
| Operating margin | 20.3% | 28.1% |
| Growth | ||
| Revenue growth (YoY) | +2.2% | +4.3% |
| Net profit growth (YoY) | -51.1% | +17.1% |
| Revenue CAGR (multi-year) | +19.0% | — |
| Financial health | ||
| Debt to equity | 0.43 | — |
| Momentum | ||
| 1-month return | +1.4% | +1.0% |
| 1-year return | -2.3% | -11.3% |
| 3-year CAGR | +17.5% | +4.2% |
| 5-year CAGR | +0.9% | +5.6% |
| 10-year CAGR | +9.3% | +18.8% |
| Distance from 52W high | -17.2% | -12.8% |
| Technicals | ||
| RSI (14) | 59 | 52 |
| Price vs 200-day avg | -6.4% | -1.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Biocon | Abbott India |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✗ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 3/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Biocon or Abbott India?
Biocon has a market cap of ₹59,497 Cr and Abbott India has a market cap of ₹55,983 Cr as of 06 Nov 2026.
Which has a lower P/E, Biocon or Abbott India?
Abbott India has the lower P/E: Biocon trades at 131.6 and Abbott India at 34.7.
Which gave better returns in the last year, Biocon or Abbott India?
Biocon did better: Biocon returned -2.3% and Abbott India returned -11.3% over one year.
Is Biocon or Abbott India a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Biocon scores 3/10 and Abbott India scores 5/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.